Evidence map›Paper›PMID 37742327›Full record

ArticleInternational urology and nephrology2024

Utility of noninvasive biomarker testing and MRI to predict a prostate cancer diagnosis.

Mark I Sultan, Linda M Huynh, Sarah Kamil, Ahmad Abdelaziz, Muhammed A Hammad, Greg E Gin, David I Lee, Ramy F Youssef

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International urology and nephrology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mark I SultanDepartment of Urology, University of California, Irvine, Orange, CA, USA.
Linda M HuynhDepartment of Urology, University of California, Irvine, Orange, CA, USA.
Sarah KamilDepartment of Urology, University of California, Irvine, Orange, CA, USA.
Ahmad AbdelazizDepartment of Urology, University of California, Irvine, Orange, CA, USA.
Muhammed A HammadDepartment of Urology, University of California, Irvine, Orange, CA, USA.
Greg E GinDepartment of Urology, University of California, Irvine, Orange, CA, USA.
David I LeeDepartment of Urology, University of California, Irvine, Orange, CA, USA.
Ramy F YoussefDepartment of Urology, University of California, Irvine, Orange, CA, USA. ryaacoub@hs.uci.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo assess the diagnostic performance and utility of the ExoDx IntelliScore and an OPKO4K score to predict prostate cancer in men presenting with elevated PSA-both as independent predictors and in combination with clinical/MRI characteristics.

methodsPatients with elevated PSA were retrospectively reviewed. Abnormal tests were defined as an OPKO4K score ≥ 7.5% and an ExoDx IntelliScore ≥ 15.6. Four regression models and ROC curves were generated based on: (1) age, PSA, and DRE, (2) model 1 + OPKO4K 4Kscore ≥ 7.5%, (3) model 2 + ExoDx IntelliScore ≥ 15.6, and (4) model 3 + MRI PIRADS 4-5.

results359 men received an OPKO4K test, 307 had MRI and 113 had ExoDx tests. 163 men proceeded to prostate biopsy and 196 (55%) were saved from biopsy. Mean age was 65.0 ± 8.7 years and mean PSA was 7.1 ± 6.1 ng/mL. Positive biopsies were found in 84 (51.5%) men. The sensitivity and negative predictive value of an OPKO4K score were 86.7% and 72.3%; values for an ExoDx test were 76.5% and 77.1%, respectively. On regression analysis, clinical markers (Age, PSA, DRE) generated an AUC of 0.559. The addition of an OPKO4K score raised the AUC to 0.653. The stepwise addition of an ExoDx score raised the AUC to 0.766. The combined use of both biomarkers, patient characteristics, and MRI yielded an AUC of 0.825.

conclusionThis analysis demonstrates the high negative predictive value of both the OPKO4K score and ExoDX IntelliScore independently while demonstrating that the combination of an OPKO4K score, an ExoDX IntelliScore, and MRI increases predictive capability for biopsy confirmed prostate cancer.

Indexed as

ProstateProstatic NeoplasmsAgedBiomarkers, TumorBiopsyHumansMagnetic Resonance ImagingMaleMiddle AgedProstate-Specific AntigenRetrospective StudiesBiomarkers, TumorProstate-Specific Antigen4K scoreExoDx IntelliScoreNoninvasive prostate cancer testingProstate biopsyProstate MRI

Identifiers

PMID37742327
PMCPMC10808487

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.